Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 1.23B P/E - EPS this Y 5.90% Ern Qtrly Grth -
Income -220.01M Forward P/E -5.73 EPS next Y 6.60% 50D Avg Chg -1.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -1.00%
Dividend N/A Price/Book 2.18 EPS next 5Y - 52W High Chg -28.00%
Recommedations 1.70 Quick Ratio 13.29 Shares Outstanding 68.32M 52W Low Chg 41.00%
Insider Own 4.74% ROA -25.74% Shares Float 43.76M Beta 1.21
Inst Own 105.00% ROE -46.79% Shares Shorted/Prior 4.86M/6.06M Price 21.32
Gross Margin - Profit Margin - Avg. Volume 572,541 Target Price 15.50
Oper. Margin - Earnings Date Nov 5 Volume 815,055 Change 3.80%
About Replimune Group, Inc.

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Replimune Group, Inc. News
04:05 PM Replimune Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway
11/12/24 Replimune Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update
11/09/24 Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024)
11/08/24 Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/30/24 Replimune to Present at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
10/07/24 Morgan Stanley's Strategic Reduction in Replimune Group Inc Holdings
10/02/24 Replimune Group, Inc. (NASDAQ:REPL) Shares Could Be 48% Below Their Intrinsic Value Estimate
10/01/24 Replimune to Present at Two Upcoming Investor Conferences
09/15/24 Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at European Society for Medical Oncology (ESMO) Congress 2024
09/09/24 Replimune Announces Positive Pre-BLA Meeting with FDA and Confirms BLA Submission On Track for 2H 2024
09/05/24 Stockholders Vote to Elect Madhavan Balachandran to Board of Directors
08/22/24 Replimune Announces Late-Breaking Abstract of IGNYTE Clinical Trial Primary Analysis Selected for Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2024
08/14/24 Replimune kickstarts Phase III melanoma trial studying RP1 immunotherapy
08/13/24 Replimune Announces First Patient Dosed in IGNYTE-3 Clinical Trial in Advanced Melanoma
08/08/24 Replimune Reports Fiscal First Quarter 2025 Financial Results and Provides Corporate Update
06/13/24 Replimune Announces $100 Million Private Placement Financing
06/07/24 Replimune (REPL) Gains on Positive Data From Melanoma Study
06/07/24 Replimune to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
06/06/24 Sector Update: Health Care Stocks Higher in Late Afternoon Trading
06/06/24 Why Is Mid-Cap Cancer-Focused Replimune Stock Trading Higher On Thursday?
REPL Chatroom

User Image drasa855 Posted - 55 minutes ago

$REPL $EYEN $VRPX $SKK on watch for morning movers! like the after hours action!

User Image vslahm Posted - 1 hour ago

$REPL it will go down always the good news= going down of stock prices in biotech industry.

User Image PennyConnection1 Posted - 1 hour ago

$REPL @Pinto72 what’s that Jerry? Cause I sure

User Image Irish_lass Posted - 1 hour ago

$REPL https://ir.replimune.com/news-releases/news-release-details/replimune-receives-breakthrough-therapy-designation-rp1-and

User Image Irish_lass Posted - 1 hour ago

$REPL

User Image Ixnay84 Posted - 1 hour ago

$REPL is bringing $IOVA down... 😑😑

User Image PennyConnection1 Posted - 2 hours ago

$REPL finally!

User Image blippi2024 Posted - 2 hours ago

$REPL lets goooooo $SMCI $NVDA $OCGN $BCTX

User Image Longterm_Inv Posted - 2 hours ago

$REPL Congratulations https://www.tipranks.com/news/the-fly/replimune-submits-rp1-bla-to-fda-receives-breakthrough-therapy-designation

User Image djjonh Posted - 2 hours ago

$IOVA $repl

User Image Pinto72 Posted - 1 day ago

$REPL πŸš€πŸš€πŸš€

User Image Bornjever Posted - 1 week ago

$REPL this stock was approved on Saturday for stage 3 approval on cancer that offers fairly good news for folks that had little hope before and now extra 2-3 years by which time there will be more cures for all of us. Now we should see a little happiness since this is approved and now PDUFA should be scheduled by May or June of next year. At 12.00 dollars and change this is a bargain???

User Image Irish_lass Posted - 1 week ago

$REPL

User Image S_Franconi Posted - 1 week ago

$REPL β€œThe initial biomarker analyses included in the SITC presentation which demonstrate increases in tumor CD8+ T cell infiltration and PD-L1 expression along with the induction of an immune inflammatory gene signature after treatment, further support the intended mechanism of RP1 in combination with nivolumab, including its ability to induce a systemic response after progression on prior anti-PD1 therapy,” said Kostas Xynos, MD, PhD, MBA, Chief Medical Officer of Replimune. β€œWe believe that the systemic activity of RP1 and nivolumab is in particular demonstrated by the similar level of responses seen in both injected and non-injected lesions, including hard to treat visceral lesions, and by the durability of the responses seen.” https://ir.replimune.com/news-releases/news-release-details/replimune-presents-late-breaking-abstract-featuring-data-ignyte

User Image S_Franconi Posted - 1 week ago

$REPL November 9, 2024 1:00 PM EST Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024) https://ir.replimune.com/news-releases/news-release-details/replimune-presents-late-breaking-abstract-featuring-data-ignyte

User Image Bornjever Posted - 2 weeks ago

$REPL yes this has FDA date of Saturday for level 3 approval but probably tomorrow and also nice to see Baker Brothers bought 500,000 shares and they already had 9.50 million. The big boys have backed up the truck and show 109 percent owned by them. This could hit 20 -40 per share by tomorrow or Monday. Wish I had more money to buy with. May have to sell some other stuff.

User Image Doozio Posted - 2 weeks ago

Da FUTUre of 🧠⏰ is in RYTM NOW as NEXN it’s going TTWO $repl Jabroni πŸ‘ INTA πŸ§ β°β™ΎοΈ

User Image Irish_lass Posted - 2 weeks ago

$REPL

User Image justiceforb_85 Posted - 2 weeks ago

$REPL would this company have a MOAT for oncolytic therapy in melanoma and microsatellite instability colon cancer?

User Image Bullish_Swagger Posted - 2 weeks ago

Upcoming Bio data - $VKTX $LPCN $REPL $IMMP $GALT

User Image Doozio Posted - 2 weeks ago

Dips are a 🎁 FOUR da $INCY bincy spider as da 🧠 has just began to EXEL up da water spout in 🧠⏰. it ain’t even in $RYTM yet during πŸ§ β°β™ΎοΈ. Just wUtch them $repl da bum πŸ‘ from here.

User Image Pinto72 Posted - 10/24/24

$REPL πŸš€πŸš€πŸš€

User Image djjonh Posted - 10/23/24

$IOVA $REPL Breaking out 😳😳

User Image PennyConnection1 Posted - 10/22/24

$REPL $VERU $BLUE

User Image Doozio Posted - 1 month ago

Chop chop huckleberries as a πŸ§ πŸ‘€ becomes da FUTUre of 🧠⏰ n if no faatch πŸ’£ lands them bum πŸ‘ will get $repl ed n start CHSN during πŸ§ β°β™ΎοΈ

User Image Pinto72 Posted - 1 month ago

$REPL πŸš€πŸš€πŸš€

User Image DimaCoins Posted - 1 month ago

$REPL Noice! Cheering you on! GLTA

User Image PennyConnection1 Posted - 1 month ago

$REPL presentation today at noon https://ir.replimune.com/events/event-details/bmo-2024-oncology-summit

User Image Irish_lass Posted - 1 month ago

$REPL And we are

User Image rahmanoof Posted - 1 month ago

$REPL we just started

Analyst Ratings
JP Morgan Overweight Sep 24, 24
HC Wainwright & Co. Buy Sep 16, 24
HC Wainwright & Co. Buy Sep 10, 24
Roth MKM Buy Aug 27, 24
JP Morgan Overweight Aug 13, 24
Barclays Overweight Jun 7, 24
HC Wainwright & Co. Buy Jun 7, 24
Barclays Overweight Dec 6, 23
HC Wainwright & Co. Buy Nov 13, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Xynos Konstantinos Chief Medical Office.. Chief Medical Officer Nov 16 Sell 10.92 7,313 79,858 112,714 11/17/23
Sarchi Christopher Chief Commercial Off.. Chief Commercial Officer Nov 16 Sell 10.92 5,255 57,385 72,245 11/17/23
Esposito Pamela Chief Business Offic.. Chief Business Officer Sep 11 Sell 20.01 5,658 113,217 263,436 09/13/23
Esposito Pamela Chief Business Offic.. Chief Business Officer Sep 11 Option 3.3 5,658 18,671 263,736 09/13/23
Esposito Pamela Chief Business Offic.. Chief Business Officer Aug 22 Sell 20.01 18,600 372,186 263,436 08/24/23
Esposito Pamela Chief Business Offic.. Chief Business Officer Aug 22 Option 9.4 18,600 174,840 282,036 08/24/23
Esposito Pamela Chief Business Offic.. Chief Business Officer Aug 11 Sell 20 1,400 28,000 263,436 08/15/23
Esposito Pamela Chief Business Offic.. Chief Business Officer Aug 11 Option 3.3 1,400 4,620 264,836 08/15/23
Esposito Pamela Chief Business Offic.. Chief Business Officer Jul 10 Sell 21.38 20,000 427,600 263,436 07/11/23
Esposito Pamela Chief Business Offic.. Chief Business Officer Jul 10 Option 9.4 20,000 188,000 283,436 07/11/23
Lewis Tanya Chief Dev. Op. Offic.. Chief Dev. Op. Officer Jun 13 Sell 23.78 12,860 305,811 135,293 06/15/23
Patel Sushil Chief Strategy Offic.. Chief Strategy Officer Jun 13 Sell 23.78 5,698 135,498 148,873 06/15/23
Patel Sushil Chief Strategy Offic.. Chief Strategy Officer May 16 Sell 18.05 15,575 281,129 154,571 05/18/23
Coffin Robert President & Chief R&.. President & Chief R&D Officer May 16 Sell 18.05 7,861 141,891 1,833,336 05/18/23
Lewis Tanya Chief Dev. Op. Offic.. Chief Dev. Op. Officer May 16 Sell 18.05 12,207 220,336 148,153 05/18/23
Love Colin Chief Operating Offi.. Chief Operating Officer May 16 Sell 18.05 10,775 194,489 794,960 05/18/23
Franchi Jean M. Chief Financial Offi.. Chief Financial Officer May 16 Sell 18.05 11,351 204,886 128,748 05/18/23
Xynos Konstantinos Chief Medical Office.. Chief Medical Officer May 16 Sell 18.05 771 13,917 120,027 05/18/23
Esposito Pamela Chief Business Offic.. Chief Business Officer May 16 Sell 18.05 5,966 107,686 263,436 05/18/23
Astley-Sparke Philip Chief Executive Offi.. Chief Executive Officer May 16 Sell 18.05 17,902 323,131 1,525,278 05/18/23
Esposito Pamela Chief Business Offic.. Chief Business Officer Dec 09 Option 1.01 15,000 15,150 244,402 12/13/22
Esposito Pamela Chief Business Offic.. Chief Business Officer Dec 09 Sell 25.03 15,000 375,450 229,402 12/13/22
Love Colin Chief Operating Offi.. Chief Operating Officer May 16 Sell 14.59 6,324 92,267 765,735 05/18/22
Esposito Pamela Chief Business Offic.. Chief Business Officer May 16 Sell 14.59 3,507 51,167 229,402 05/18/22
Franchi Jean M. Chief Financial Offi.. Chief Financial Officer May 16 Sell 14.59 3,436 50,131 95,099 05/18/22
Lewis Tanya Chief Dev. Op Office.. Chief Dev. Op Officer May 16 Sell 14.59 5,473 79,851 120,360 05/18/22
Patel Sushil Chief Commercial Off.. Chief Commercial Officer May 16 Sell 14.59 10,687 155,923 130,146 05/18/22
Coffin Robert President & Chief R&.. President & Chief R&D Officer May 16 Sell 14.59 5,737 83,703 1,796,197 05/18/22
Astley-Sparke Philip Chief Executive Offi.. Chief Executive Officer May 16 Sell 14.59 9,632 140,531 1,401,080 05/18/22
Omega Fund IV, L.P. 10% Owner 10% Owner Mar 14 Option 9.78 16,500 161,370 4,779,880 03/16/22
Omega Fund IV, L.P. 10% Owner 10% Owner Mar 14 Sell 15.48 106,500 1,648,620 4,673,380 03/16/22
Omega Fund IV, L.P. Director Director Nov 16 Sell 33.5 2,594 86,899 4,808,804 11/18/21
Omega Fund IV, L.P. Director Director Nov 12 Sell 33.66 24,017 808,412 4,811,398 11/16/21
Love Colin Chief Operating Offi.. Chief Operating Officer Oct 15 Sell 30.35 30,000 910,500 745,809 10/19/21